SEC Watching Press Releases, Wants Context For “Preliminary” Trial Results
This article was originally published in The Pink Sheet Daily
Executive Summary
Drug companies should also fully disclose their role in developing the drug being discussed and accurately describe the drug’s stage of development, SEC tells FDLI conference. FDA says there is “no conspiracy” to increase role in investor communications oversight.